Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1750224 | 1.00 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL8444462 | 0.92 | GPR84 (0.31) | SMN1; SMN2 | |
| SCHEMBL2002395 | 0.88 | ALDH1A1 (0.43) | SMN1; SMN2 | |
| SCHEMBL1999339 | 0.88 | ALDH1A1 (0.38) | SMN1; SMN2 | |
| SCHEMBL11441731 | 0.86 | MAPT (0.40) | — | |
| Hydrochloric Acid SCHEMBL11570074 | 0.86 | TDP1 (0.30) | — | |
| SCHEMBL2003865 | 0.85 | — | — | |
| SCHEMBL11570297 | 0.82 | LCK (0.31) | — | |
| SCHEMBL209332 | 0.81 | — | — | |
| SCHEMBL14813236 | 0.81 | MAPT (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713806-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2013-05-08 | — | — | EP | claimed |
| US-7968557-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | NOVARTIS AG (CH) | 2011-06-28 | — | — | US | claimed |
| US-20070225306-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2007-09-27 | — | — | US | claimed |
| EP-1713806-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2006-10-25 | — | — | EP | claimed |
| WO-2005107760-A1 | COMPOUNDS AND COMPOSITIONS AS INDUCERS OF KERATINOCYTE DIFFERENTIATION | IRM LLC (BM) | 2005-11-17 | — | — | WO | claimed |
| WO-2005080393-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-09-01 | — | — | WO | claimed |
| EP-1713806-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2013-05-08 | — | — | EP | disclosed |
| US-7968557-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | NOVARTIS AG (CH) | 2011-06-28 | — | — | US | disclosed |
| EP-1296973-B1 | GUANIDINE DERIVATIVES OF QUINAZOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-20070225306-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2007-09-27 | — | — | US | disclosed |
| EP-1713806-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005107760-A1 | COMPOUNDS AND COMPOSITIONS AS INDUCERS OF KERATINOCYTE DIFFERENTIATION | IRM LLC (BM) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005080393-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-09-01 | — | — | WO | disclosed |
| EP-0822544-B1 | Optical recording medium | MITSUI CHEMICALS INC (JP) | 2001-01-03 | — | — | EP | disclosed |
| US-5955464-A | USE OF THE RECEPTOR TYROSINE KINASE INHIBITORY PROPERTIES OF THE COMPOUNDS IN THE TREATMENT OF PROLIFERATIVE DISEASE SUCH AS CANCER | ZENECA LIMITED (GB) | 1999-09-21 | — | — | US | disclosed |
| US-5948593-A | CONTAINING A PIPYRROMETHENE METAL CHELATE COMPOUND | MITSUI CHEMICALS, INC. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0794953-B1 | QUINAZOLINE DERIVATIVES | ZENECA LTD (GB) | 1999-05-06 | — | — | EP | disclosed |
| EP-0822544-A1 | Optical recording medium | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1998-02-04 | — | — | EP | disclosed |
| EP-0794953-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996016960-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225306-A1 | Compounds and Compositions as Protein Kinase Inhibitors | ABL1, PDGFRA, PDGFRB | SMN1; SMN2 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.